What to Do if Your Plan Doesn't Cover Obesity Medications At All

Finding out that your insurance plan categorically excludes obesity medications is a different situation than getting a prior authorization denied. A denial usually means "not yet" or "not the way you've asked." A coverage exclusion means the plan has decided — as a policy — not to cover this category of treatment at all.

It's a harder wall to hit. But it's not necessarily a dead end.

This article covers what a coverage exclusion looks like, how to verify you're actually facing one, and what realistic options exist when you are.

First: Confirm It's Actually an Exclusion

Before you accept that your plan covers nothing, make sure you're looking at an actual categorical exclusion — not a formulary gap or a denial that could be appealed.

Here's how to tell the difference:

• A coverage exclusion is a formal policy that applies to everyone on the plan. It will appear in your plan documents under "Exclusions and Limitations." Language typically reads: "This plan does not cover weight loss medications, anti-obesity drugs, or medications used primarily for the purpose of weight reduction."
• A formulary gap means your specific medication isn't listed, but obesity drugs as a category aren't explicitly excluded. In this case, a formulary exception request may still succeed.
• A PA denial means the plan covers the category but rejected your specific request for now. This is appealable.

Check your Summary of Benefits and Coverage (SBC) and your plan's evidence of coverage. Search for words like "weight loss," "obesity," and "anti-obesity." Call member services and ask directly: "Does my plan exclude obesity medications as a category?"

If the answer is yes — confirmed in writing in the plan documents — you're dealing with a true exclusion.

Option 1: Request a Medical Necessity Exception Anyway

Even when a plan has a coverage exclusion, it's sometimes worth asking for a medical necessity exception — particularly if you have serious weight-related health conditions.

The argument is: obesity is a chronic disease. GLP-1 medications aren't cosmetic treatments; they're medically necessary interventions for a documented medical condition. For some patients, especially those with conditions like cardiovascular disease, severe sleep apnea, or diabetes risk, the case for medical necessity is strong.

Your doctor can write a detailed letter supporting this argument. It won't succeed in every case — plans have broad discretion to enforce exclusions — but it costs nothing to try, and in some cases an escalated review or a complaint to your state insurance commissioner creates enough pressure that the plan reconsiders.

Option 2: Employer Plan? Talk to HR

If you have employer-sponsored insurance, your employer — not the insurance company — made the decision to exclude obesity medications. Employers who self-fund their health plans (meaning they pay claims directly, with the insurer acting only as an administrator) have a lot of flexibility in designing their benefits.

This matters because the right conversation might not be with your insurance company at all — it might be with your HR department or benefits administrator.

You can:

• Ask HR whether obesity medications were considered when designing the plan
• Share information about the health and productivity impact of untreated obesity
• Ask whether coverage will be reconsidered at the next plan year

This approach is more effective when multiple employees are raising the same concern, or when there's documentation linking obesity treatment to reduced absenteeism and lower long-term healthcare costs. Individual advocacy can work, but it's a slower path.

Option 3: Manufacturer Patient Assistance Programs

The companies that make GLP-1 medications offer assistance programs for patients who can't access or afford their medications. These programs vary and have eligibility requirements, but they're worth exploring seriously.

What these programs typically offer:

• Copay savings cards (commercial insurance only): For patients with commercial insurance — not Medicare or Medicaid — manufacturers typically offer cards that reduce out-of-pocket costs at the pharmacy. These won't help if you have no insurance coverage at all, but they can dramatically reduce what you pay if you have partial coverage.
• Patient assistance programs (income-based): For patients who are uninsured or underinsured and meet income thresholds, manufacturers may offer free or heavily discounted medication. Eligibility and application processes vary.

To explore these, search for the medication's official website and look for "savings" or "patient support" sections. Your doctor's office may also have resources or can connect you with a patient navigator who handles these applications.

Important: these programs are not guaranteed, can change over time, and have their own eligibility criteria. They're worth exploring as a bridge while you work on longer-term coverage solutions.

Option 4: Switch Plans During Open Enrollment

If your current plan excludes obesity medications and you're not satisfied with other options, open enrollment is your most direct path to a plan that covers them.

During open enrollment — whether through your employer, through the Affordable Care Act marketplace, or through Medicare — you can switch to a plan with better coverage. Before you do, verify:

1. Look up your specific medications in the new plan's formulary (by name, not just category)
2. Confirm whether prior authorization is required and what the clinical criteria are
3. Review the tier and cost-sharing so you understand what you'll actually pay

This requires homework, but it's the most durable solution. See our article on how to pick a plan that covers your medication for a step-by-step guide.

Option 5: Consider Cash Pay and Compounded Options

Some patients choose to pay out of pocket when insurance doesn't cover their medication. For branded GLP-1 medications, this is expensive — often several hundred dollars per month or more. But it's a real option some patients choose while pursuing coverage or assistance.

A few things worth knowing:

• Compounded semaglutide and tirzepatide: During periods when branded GLP-1s were in shortage, compounding pharmacies were permitted by the FDA to produce compounded versions of these medications. The regulatory status of compounded GLP-1s is complex and has changed over time; whether they remain available depends on FDA policies in effect at the time you're reading this. Ask your doctor about the current landscape and whether a compounded option is appropriate and legal in your situation.
• Cash-pay pricing: Some pharmacies offer lower self-pay prices than the retail sticker price, especially with discount programs. Your doctor's office may be familiar with options in your area. There are several online pharmacy options for GLP-1 medications that include manufacturer-run pharmacies that usually offer the best cash pay price.

This is an area where the right path depends heavily on your individual situation, your doctor's judgment, and current regulatory conditions. Talk to your doctor before pursuing any compounded medication. Also beware of unapproved or 'for research use only' peptides that can be purchased online without a prescription. These are not medical products and should not be used by patients.

Option 6: Address Related Diagnoses That May Have Separate Coverage

If you have a weight-related condition — like type 2 diabetes, prediabetes, or cardiovascular disease — your doctor may be able to prescribe a GLP-1 medication under that indication instead of the obesity indication.

For example:

• Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction. If you have those conditions, it may be covered under your plan's diabetes or cardiology benefits, even if obesity drugs are excluded.
• Mounjaro is FDA-approved for type 2 diabetes.

This is a nuanced clinical and coverage question — your doctor needs to determine whether a different medication or indication is appropriate for you. It's not always an option, and it's not something to do without clinical guidance. But it's a legitimate pathway worth discussing.

The Bigger Picture: Advocacy Matters

Many Americans are in this situation. The exclusion of obesity medications from insurance plans is a policy decision, and it's one that patient advocacy groups, medical societies, and obesity medicine physicians are actively working to change. Federal legislation has been introduced in recent years to require coverage of obesity medications under Medicare and to strengthen protections in employer plans.

This doesn't help you right now. But it means the landscape is changing, and coverage that doesn't exist today may exist in the future — which is one more reason to keep the conversation going with your doctor and to document your treatment needs.

The Bottom Line

A categorical coverage exclusion is a harder obstacle than a denial, but it's not the end. Explore patient assistance programs, talk to HR if you have employer coverage, look carefully at your open enrollment options, and have a candid conversation with your doctor about what paths make clinical and practical sense for you. There's rarely only one road forward.